11 Jun 2019

Melvyn’s story

In 2012 Melvyn, a bone marrow transplant patient, suffering from an aggressive form of graft-versus-host-disease was given pioneering, life-saving treatment, Mesenchymal Stem Cell Therapy, at The Catherine Lewis Centre.

“I was first diagnosed with leukaemia in July 1998 after complaining of fatigue to my local GP,” says Melvyn.

“I didn’t know what the disease was at the time but my wife Pauline took the news very badly as she understood what the outcome could be.

“I wanted to see my children graduate – my daughter was 13 and my son 15 – so I was determined to fight it and stay positive. It was a huge shock for my family.”

Melvyn successfully underwent a stem cell transplant just 10 weeks later, and although he responded well initially he started to experience a serious complication called graft-versus-host-disease (GvHD), where the newly transplanted cells attack the recipient’s body.

“I remember reaching out to turn the bedside lamp off and noticing for the first time hard lumps on my arms. By the time I went to clinic, it had spread all over my body from my neck to my ankles and my skin had become so thick that I found it hard to move.

“I saw the rheumatologist and started a new steroid drug regime, it worked well for around two years, but the risk of infection and relapse were so high that I stopped taking them.

“After a couple of years GvHD deteriorated; but thankfully, because of research funded by Leukaemia UK, I was given the opportunity to trial a new treatment called Mesenchymal Stem Cell Therapy, which has significantly improved my life.”

Professor Francesco Dazzi

“Leukaemia UK has enabled us to initiate this treatment and gather preliminary evidence with some extraordinary results. In Melvyn’s case, we isolated cells taken from his daughter, prepared them here at The Catherine Lewis Centre and, when they were ready, we infused them.

“We have seen a 50% improvement in Melvyn’s condition and I am thrilled that we have been able to improve both his outlook and quality of life.”

Related posts

A decade on: Dr Javier Redondo Muñoz continues to shape the future of Leukaemia research

18 May 2026

A decade on: Dr Javier Redondo Muñoz continues to shape the future of Leukaemia research

Ten years after joining the second cohort of Leukaemia UK’s John Goldman Fellowships (JGF), Dr Javier Redondo Muñoz is continuing to shape the future of leukaemia research. Now leading his own team in…

Leukaemia UK’s Patient Care Pioneer Award fuels innovative research to revolutionize ‘watch and wait’ approach

18 November 2024

Leukaemia UK’s Patient Care Pioneer Award fuels innovative research to revolutionize ‘watch and wait’ approach

Leukaemia UK is excited to announce Professor Francesco Forconi from University Hospital Southampton (UHS) as the first recipient of its Patient Care Pioneer Award. Through this new funding initiative, Professor…

Leukaemia UK launches new Patient Care Pioneer Award funding initiative

19 February 2024

Leukaemia UK launches new Patient Care Pioneer Award funding initiative

Leukaemia UK is delighted to launch a brand-new funding scheme in 2024, intended specifically for innovative, patient-focussed applied research and targeting UK-based healthcare professionals.   The first of its kind for…

John Goldman Fellowship awarded to Dr Pramila Krishnamurthy

29 November 2021

John Goldman Fellowship awarded to Dr Pramila Krishnamurthy

Leukaemia UK is proud to announce Dr Pramila Krishnamurthy of King’s College Hospital and King’s College London as a Leukaemia UK John Goldman Fellow co-funded by Rosetrees Trust. Dr Krishnamurthy will be using the fellowship to better understand why some leukaemia patients relapse following a stem cell transplant, and how donor lymphocyte infusion can help prevent this.